
About this episode
Guest: Thomas Caulfield, Ph.D.
Host: Amit K Ghosh, M.D., MBA (@AmitGhosh006)
In this podcast, Dr. Thomas Caulfield from Mayo Clinic Florida describes a novel approach for SARS-CoV2 multi-drug targeting using artificial intelligence. Dr. Caulfield is leading a national team of investigators from Harvard, University of California, In Vivo Biosystems and Mayo Clinic to perform large-scale in silico and in vivo experiments on de novo drugs to better understand COVID-19 and halt its progression. University of California hosts a live virus BSL3 facility for rapidly screening novel compounds that Dr. Caulfield's lab designs in silico and refines with feedback using machine learning techniques and data layering.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Get every episode summarized
Each time Mayo Clinic Talks publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Mayo Clinic Talks

Advancements in the Diagnosis and Treatment of Parkinson’s Disease
Mayo Clinic Talks

Parkinson’s Disease in Children and Young Adults
Mayo Clinic Talks

Mayo Clinic Proceedings: Diabetes and Novel Therapies for Diabetes
Mayo Clinic Talks

Mayo Clinic Proceedings: Healthy Aging
Mayo Clinic Talks